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Background: Non-cardiovascular comorbidities are recognised as independent prognostic factors in selected
heart failure (HF) populations, but the evidence on non-selected HF and how comorbid disease severity and
change impacts on outcomes has not been synthesised. We identiﬁed primary HF comorbidity follow-up studies
to compare the impact of non-cardiovascular comorbidity, severity and change on the outcomes of quality of life,
all-cause hospital admissions and all-cause mortality.
Methods: Literature databases (Jan 1990–May 2013) were screened using validated strategies and quality ap-
praisal (QUIPS tool). Adjusted hazard ratios for the main HF outcomes were combined using random effects
meta-analysis and inclusion of comorbidity in prognostic models was described.
Results: There were 68 primary HF studies covering nine non-cardiovascular comorbidities. Most were on diabe-
tesmellitus (DM), chronic obstructive pulmonary disease (COPD) and renal dysfunction (RD) for the outcome of
mortality (93%) and hospital admissions (16%), median follow-up of 4 years. The adjusted associations between
HF comorbidity and mortality were DM (HR 1.34; 95% CI 1.2, 1.5), COPD (1.39; 1.2, 1.6) and RD (1.52; 1.3, 1.7).
Comorbidity severity increasedmortality frommoderate to severe disease by an estimated 78%, 42% and 80% re-
spectively. The risk of hospital admissions increased up to 50% for each disease. Few studies or prognosticmodels
included comorbidity change.
Conclusions:Non-cardiovascular comorbidity and severity signiﬁcantly increases the prognostic risk of poor out-
comes in non-selected HF populations but there is a major gap in investigating change in comorbid status over
time. The evidence supports a step-change for the inclusion of comorbidity severity in new HF interventions to
improve prognostic outcomes.
© 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Non-cardiovascular (CVD) comorbidity is common in heart failure
(HF) and is well known to inﬂuence its prognosis [1,2] which may
occur through shared risk factors [3,4] or direct pathophysiological
links [5–8]. For non-cardiovascular diseases in HF, the currentNational Institute for Health
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eliability and freedom from bias
land Ltd. This is an open access articlcomorbidity focus has been on conditions such as diabetes and chronic
kidney disease (CKD) in selected populations. The range of potential
non-cardiovascular comorbidity is most commonly identiﬁed in the
general non-selected HF population and yet current investigations
have focused on distinct prognostic factors associated with aetiology
[9] or HF sub-groups selected by ejection fraction [10,11]. To capture
the HF spectrum [12] we focused on the general non-selected popula-
tion to identify the fullest range of non-CVD comorbidity and identiﬁed
studies which could support the development of better prognostic
models.
Current evidence on cardiovascular comorbidity such as hyperten-
sion or ischemic heart disease [13–15] has shown that severity is asso-
ciated with poor HF outcomes [16,17]. Evidence from CKD studies also
shows that severity and additionally change in status are important de-
terminants of higher hospital admissions and mortality [18,19]. The
combined evidence for cardiovascular comorbidity and CKD severity
in HF, generates the hypothesis that weighting of other non-CVD co-
morbidities by severity and its change over time may provide bettere under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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comes. This evidence is vital if precise comorbidity measurements are
incorporated into practical applications of prognosis and for developing
new interventions to improve outcomes. Prognostic models, which in-
corporate comorbidity severity and change, need to apply to the broad
spectrum of HF and to the life course of outcomes from diagnosis and
quality of life, to end-stage disease, hospital admissions and death.
We conducted a systematic review to synthesise the current evi-
dence on non-CVD comorbidity in the non-selected general population
of HF. We postulated two hypotheses: (i) the prognostic risk estimates
for the association between chronic disease comorbidities and quality
of life, hospital admissions and mortality outcomes in non-selected HF
would differ by comorbid disease and (ii) increasing comorbidity sever-
ity and change in HFwould be associatedwithworse quality of life, hos-
pital admissions and mortality outcomes.
2. Methods
A systematic review proposal was registered with PROSPERO (protocol no.
CRD42013003605—www.crd.york.ac.uk/prospero/) and peer reviewed by the Cochrane
Prognosis Methods group. The development stages were: (i) literature searching of key
databases, (ii) screening and selection of articles using inclusion criteria, (iii) extraction
using structured data collection, (iv) quality appraisal of the selected articles and
(v) narrative and meta-analyses of the study ﬁndings. We used PRISMA [20] and
MOOSE [21] international guidelines for reporting the review andmeta-analysis (Supple-
mentary material online, Appendices S1.1 and 1.2).
2.1. Literature searches
We searchedMEDLINE, EMBASE and CINAHL for studies published between January 1st
1990 and 1st May 2013. Validated search strategies for prognosis follow-up studies [22,23]
were combined with HF population and outcome search strings that included quality of
life, hospital admission and mortality terms (Supplementary material online, Appendix S2).
The search approaches were validated by the following: (i) 3 cardiology physicians,
(ii) comparison with prior HF-focused prognosis systematic reviews with similar inclusion
criteria [24,25] and (iii) comparison with key comorbidity prognosis articles. Additional
searches included unpublished studies, reference lists and citations, key journals and com-
munication with international HF experts from Europe and the United States.
2.2. Study selection
Eligible cohort studies in adults 18 years and overwith de novo or chronic HF and two
ormoremonths of follow-up were identiﬁedwith quality of life, all-cause hospital admis-
sions or all-cause mortality as outcomes. These studies had not selected HF samples by
aetiology, ejection fraction or surgical intervention and diagnosiswas based on either clin-
ical assessment [26], medical record diagnosis or an administration code. Excluded studies
had either used composite outcomes or been published in non-English journals.
Abstract screening identiﬁed cohort studies investigating (i) the association between
a primary non-cardiovascular disease comorbidity in HF and outcome, labelled ‘chronic
disease focus’ prognostic factor studies, (ii) a number of potential prognostic factors in-
cluding a non-cardiovascular comorbidity as an independent and signiﬁcant factor,
labelled as ‘general’ prognostic factor studies and (iii) prognostic model studies that com-
bined two or more factors, including a non-cardiovascular comorbidity, to estimate risk.
RCTs were only included if they were conducted in non-selected HF as deﬁned in this re-
view and where both trial arms were used for the prognosis study, which is the recom-
mended approach given the often negligible effect of the intervention [27]. Two
independent reviewers with a third for arbitration selected abstracts for full paper review
based on inclusion criteria.
2.3. Deﬁnition of comorbidity
Comorbidity was deﬁned as any non-cardiovascular disease in HF based on a clinical
diagnosis, administration code or patient self-report. In addition to the comorbidity dis-
ease status, we also identiﬁed, where possible, indicators of severity which included com-
plications, drugs, healthcare use episodes and physiological markers used in current
diagnostic frameworks. In an initial literature scoping exercise, the clear current evidence
for comorbidity in HF was for CKD with two completed systematic reviews [28,29], but
only studies meeting our study inclusion criteria were included from these reviews or
publications subsequent to 2005.
2.4. Data extraction from studies
All available datawere extracted using a pre-deﬁned templatewhich included the do-
mains of study characteristics, comorbidity measurement, outcome measures, statistical
analysis and results. Study characteristics included source, setting, eligibility, sample
size, mean age, methods (design, inclusion/exclusion criteria, follow-up), males (%), eth-
nicity (%), clinical HF deﬁnition, New York Heart Association (NYHA) stages 3 to 4 (%),systolicHF (%) andmean ejection fraction (EF). Comorbiditymeasures includeddeﬁnition,
type, severity or change indicator and prevalence. Outcomemeasureswere all-causemor-
tality or hospital admission or quality of life. Statistical analysis and results included the re-
gression method, variables for adjustment of confounding, number of events, non-
adjusted and adjusted effect estimates and measure of association (odds ratios or hazard
ratios). Where characteristics were reported by study sub-groups, whole study group es-
timates were calculated or extracted.
For the ‘chronic disease focus’ HF prognostic factor studies, signiﬁcant and non-
signiﬁcant effect estimates were extracted for the most adjusted primary comorbid dis-
ease exposure and not additional chronic diseases included as confounders (these con-
founders are likely to have their own unconsidered confounding). For the ‘general’
prognostic factor and model HF studies, only comorbid chronic diseases that were signif-
icant in the ﬁnal adjusted analyses were extracted as non-signiﬁcant exposure effects are
mostly unreported.
2.5. Quality appraisal
We used the Quality in Prognosis Studies Tool (QUIPS) [30] to evaluate the risk of
study bias in six domains: participation, attrition, prognostic factor measurement, out-
come measurement, study confounding, statistical analysis and reporting. We recorded
selected objective criteria in the QUIPs tool, other internal and external validity markers
[31] and criteria for prognosticmodels to assess the risk of bias for each domain (low, me-
dium and high risk) (Supplementary material online, Appendix S3).
This assessment informed the study inclusion inmeta-analysis and sensitivity analysis
of combined effects, removing studies with one or more individual domains at high risk.
Inter-rater agreement for overall study riskwasmeasuredusing Cohen's kappa coefﬁcient.
2.6. Statistical analysis
Meta-analysismethodswere applied using a speciﬁed inclusion format to a sub-set of
chronic disease focus HF prognostic factor studies as they had not been selected on the
basis of the signiﬁcance or independenceof the comorbidity exposure. Individual study re-
sults were reported when meta-analysis was not possible due to low numbers of studies
for speciﬁc outcomes and summaries of the ‘general’ prognostic factor and model studies
by each chronic disease were provided.
The only primary studies identiﬁed that included a severitymeasurewere for diabetes
mellitus (DM), chronic obstructive pulmonary disease (COPD) and chronic kidney disease
(CKD) inHF. The known indicators of severity and changewere glycosylated haemoglobin
(HbA1c) for DM and forced expiratory volume in 1 s (FEV1) for COPD. The framework for
measuring renal function and change in HF studies was based on eGFR or creatinine (Cr).
The broader term ‘renal dysfunction’ (RD) could also include normal to sub-threshold
renal function levels without underlying and established CKD. So based on guidelines
[32] ‘any renal dysfunction’ was deﬁned as eGFR of b60 mL/min/1.73 m2, with severity
level deﬁned as mild (60–89), moderate (30–59) and severe (b30 mL/min) compared
to the reference category. Moderate change in severity was deﬁned as an increase in cre-
atinine (Cr) of ≥0.3mg/dL fromhospital baseline to study deﬁned end point and severe in-
crease in severity as an increase in Cr of ≥0.5 mg/dL.
Random effects meta-analysis (DerSimonian and Laird method) [33] was used to
combine maximally adjusted hazard ratios (HRs) from individual studies using Metan in
Stata version 13. This method assumes that the exposure effects differ across studies
and takes account of between and within study variation by adjusting the standard errors
of the individual studies. Where meta-analysis indicated heterogeneity (I2 ≥ 40%, Chi2;
p ≤ 0.1), Galbraith plots [34] and a-priori selected potential effect modiﬁers (setting, pop-
ulation and exposure deﬁnitions and the risk of bias level) were used to perform sensitiv-
ity analysis and increase accuracy of estimates by removal of studies. Small study effects
and publication bias were investigated by funnel plots and Egger tests (p ≤ 0.1 indicating
possible publication bias) [35].
3. Results
3.1. Overall study characteristics
From a total of 10,331 studies (Supplementary material online,
Appendix S4), 68 were eligible for the review (Appendix S5 and
Table 1). There were 34 ‘chronic disease focus’ studies, 22 ‘general’
studies and 12 prognostic model studies (Supplementary material
online, Tables S1.1–3.2).
The 68 studies were based in 16 countries and 60 had more than 1-
year of follow-up, with median follow-up reported in 50 studies of
4 years [interquartile range 1 to 5 years]. Most studies were hospital-
based observational studies (60%) and 26% were RCTs. The proportion
of HF patients with systolic dysfunction was 58% and for NYHA class 3
or 4was 51%.Mortality outcomewas investigated in 63 studies, hospital
admissions in 11 and quality of life in none.
There was a high level of agreement on the overall risk score be-
tween the two reviewers (kappa coefﬁcient of 0.86). The overall risk
Table 1
Overall study characteristics for the 68 included studies.




Diabetes COPD Renal dysfunction Rheumatoid
arthritis
Study characteristics
Number of unique studies 11 5 17 1 22 12
Number of participants 138,953 7121 102,638 955 211,077 265,573
Mean study follow-up; months (m),
years (y)
6 m–7.5 y 2.9–4.5 y 6 m–6.5 y 1 y 6 m–4.7 y 2.4 m–5.2 y
Location (n)
North America 4 7 1 7 6
South America 1 1




RCT 6 1 5 1 5
Hospital 4 3 11 1 16 5
Community 1
Hospital/community 1 1 1 4 2
Population characteristics
Clinical deﬁnition
Clinical diagnosis 6 3 14 1 15 7
Clinical record 1 1
Multiple 1
Administration code 4 2 2 6 4
Unspeciﬁed 1
Mean age; years (SD) range 50 (11)–77 (12) 70 (12)–80
(IQR75–87)
62 (15)–80 (median) 45 66 (12)–86 (5) yrs 66 (11)–79 (6)
Males (%) range 46–73 50–71 43–76 77 (12) 40–71 34–98
Systolic HF (study deﬁned) (%) 47–87 25–83 36–82 51 36–79 44–90
Mean ejection fraction; % (SD) range 27 (14)–47 (13) 33 (12)–50 (16) 27 (12)–44 (16) 44 35 (14)–54 (15) 33 (9)–43 (14)
NYHA (Stage 3/4) (%) 36–84 52–95 32–84 12–96 25–55
Exposure characteristics
Prevalence % (range) 16 (13–47) 19 (17–35) Any 49 (39–79) 11 Diabetes (n = 17) 3–61% (n = 7) 14–36%
Mild 43 COPD (n = 6) 20–47% (n = 6) 10–31%
Moderate 36 (20–67) Renal dysfunction (n = 12) 1–70% (n = 5) 8–25%
Severe 6 (2–33)% Arthritis
Cancer (n = 2) 5–29% (n = 3) 2–9%
Dementia (n = 7) 2–12% (n = 3) 5–9%
Other lung
disease
(n = 2) 10–23% (n = 1) 9%
Liver disease (n = 1) 7% (n = 3) 1–3%
Exposure measure (n)
Status 9 5 8 1 20
Severity 4 1 10 4
Severity change 0 7 1
Outcomes (n)
All-cause mortality 11 5 17 1 19 10
All-cause hospital admission 1 4 4 2
Quality of life 0 0 0 0 0 0
Risk of bias (%)
Low 36 40 29 32 42
Moderate 64 60 65 1 64 58
High 6 5
Any renal dysfunction is deﬁned by eGFR b60mL/min, mild by eGFR 60–89mL/min,moderate by eGFR 30–59mL/min and severe by eGFR b30mL/min compared to the highest category.
Moderate severity change was deﬁned by an increase in creatinine (Cr) of ≥0.3 mg/dL from hospital baseline to study deﬁned end point and severe by an increase in Cr of ≥0.5 mg/dL.
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ies and high in 3% (n = 2) studies (Supplementary material online,
Tables S4.1–4.2). The risk domains with low risk scores were outcome
measurement and study attrition and high risk scores were study con-
founding and statistical analysis and reporting (Fig. 1). Nine comorbid-
ities had been investigated in HF, but meta-analysis was only possible
for DM, COPD and RD.
3.1.1. DM comorbidity in HF and mortality; meta-analysis
Nine HF and DM focused studies reported all-cause mortality rates
with a mean follow-up in individual studies of ≥6 months (range6 months to 7.5 years). Out of 135,402 HF patients (56% with LVSD),
21,455 (16%) had diabetes (range 13 to 47%). Over follow-up crudemor-
tality was 62% in HF patients with andwithout comorbid diabetes. Using
random effects model the combined adjusted mortality risk was hazard
ratio (HR) of 1.34 (95% conﬁdence interval 1.24, 1.46) (Fig. 2). Following
exclusion of a study from themeta-analysis which includedmore chron-
ically severe patients [36] identiﬁed in a Galbraith plot (Supplementary
material online, Fig. S1a), heterogeneity became non-signiﬁcant (I2 =
35%, p = 0.15). Funnel plot indicated possible publication bias (Egger
test p = 0.12) (Supplementary material online, Fig. S2a), but removal
of the two smallest studies [37,38], had little effect on the pooled
Fig. 1. The risk of bias domain summary results.
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interactions for highermortality risk in HFwere found between diabetes
status and those age 65 years or less [39], females [36,39], non-ischemic
HF aetiology (p = 0.013) [40], coronary artery disease [41] and LVSD
[42].
3.1.2. DM comorbidity severity in HF and mortality
When diabetes was stratiﬁed by treatment type, non-signiﬁcant ef-
fects were found for oral and diet treated diabetes (HR 1.38; p= 0.13
and HR 1.33; p=0.22 respectively), but the mortality effects increased
and became signiﬁcant in the undiagnosed (not treated, HR 1.69;
p b 0.01) and insulin treated group (HR 2.11; p b 0.01) [43]. This repre-
sents an estimated 78% increase in HRmortality risk from the diet to in-
sulin treated group. Increasing HbA1c levels were also reported as
increasing HF mortality risk in one study with an adjusted risk per 1%
higher HbA1c of HR 1.14 (1.06, 1.23) [44].
3.1.3. DM comorbidity in HF and mortality; general factor and
model studies
The signiﬁcant associations between DM in HF and all-causemortal-
ity ranged from HR 1.16 to 3.19 in the 14 ‘general’ prognostic factor
studies and from HR 1.34 to 2.37 in the 6 prognostic model studies
(Supplementary material online, Fig. S3a–b). A signiﬁcant interaction
was found between age and diabetes in one study with younger
group aged b85 years being associated with poorer mortality outcome
(p = 0.014) [45]. Only one of the six prognostic models had stratiﬁed
by treatment severity [46] for insulin prescription (HR 1.8; 1.56, 2.08)
and ‘other treatment’ (HR 1.5; 1.34, 1.68), but none included a change
measure.Fig. 2. Association between HF and diabetes comorbidity and all-cause mortality. Diabetes com
port. Adjusted variables: age (A), gender (G), ethnicity (E), social (S), risk factors (R), comorbid
ejection fraction (Ef).3.1.4. DM comorbidity in HF and hospital admissions
Only one DM chronic disease focused study included all-cause hos-
pital admissions which showed a signiﬁcant adjusted association (HR
1.28; 1.19, 1.38) [47]. In the 4 ‘general’ prognostic factor and 1 model
studies, the range of signiﬁcant associations with all-cause hospital ad-
missions were from HR 1.13 to 1.53 and HR 1.17 respectively (Supple-
mentary material online, Fig. S3). None of the ‘general’ prognostic
factor or model studies for hospital admissions included a comorbidity
severity or change measure.
3.1.5. COPD comorbidity in HF and mortality; meta-analysis
Five COPD focused studies reported adjusted associations with all-
cause mortality with individual study mean follow-up ranging from 1
to 8 years. Out of 7121 HF patients (54% with LVSD), 1309 (18%) had
COPD (range 17 to 35%). Over follow-up, 48% of HF patients with COPD
had died compared to 38% without COPD, and using random effects,
the combined adjusted all-cause mortality risk was HR 1.39 (1.21, 1.6)
(Fig. 3). There was marginal evidence of heterogeneity in studies (I2 =
38%, p=0.17) (Supplementarymaterial online, Fig. S1b) and publication
bias (Egger test p= 0.12) (Supplementary material online, Fig. S2b).
3.1.6. COPD comorbidity severity in HF and mortality
One study (N = 532) showed that the association between lower
COPD severity and all-cause mortality in HF was reduced, with an in-
creasing FEV1 (per 10% of predicted) being associatedwith an estimated
14% reduction in death (adjusted HR 0.86; 0.8, 0.92) [48]. The other re-
ported unadjusted estimates were: HR 1.26 (0.9, 1.8) for the moderate
COPD severity group and HR 1.68 (1.2, 2.3) for the severe group.orbidity deﬁned by clinical diagnosis, administration code, prescription or patient self-re-
ities (C), aetiology (At), heart failure severity (Sv), drugs (D), laboratory (L), physical (P),
Fig. 3. Association between HF and COPD comorbidity and all-cause mortality. COPD comorbidity deﬁned by clinical diagnosis, administration code or patient self-report. Adjusted variables:
age (A), gender (G), ethnicity (E), social (S), risk factors (R), comorbidities (C), aetiology (At), heart failure severity (Sv), drugs (D), laboratory (L), physical (P), ejection fraction (Ef).
102 C.A. Rushton et al. / International Journal of Cardiology 196 (2015) 98–1063.1.7. COPD comorbidity in HF and mortality; general factor and
model studies
The associations between COPD in HF and all-cause mortality risk
ranged from HR 1.24 to 1.7 in the 5 ‘general’ prognostic factor studies
and HR 1.23 to 1.6 in the 5 prognostic model studies (Supplementary
material online, Fig. S3d). Two of the studies included community pa-
tients [49,50] one of which compared the associated risk from COPD
on mortality in community patients (HR 1.7; 1.58, 1.82) to hospital pa-
tients (HR 1.24; 1.19, 1.31). None of the ‘general’ prognostic factor or
model studies for mortality included a comorbidity severity or change
measure.
3.1.8. COPD comorbidity in HF and hospital admissions
No HF studies were identiﬁed investigating the primary association
between COPD and hospital admissions. Only one ‘general’ prognostic
factor study and one prognostic model study included COPD to investi-
gate hospital admissions (adjusted HR 1.47; 1.3, 1.7 and odds ratio (OR)
1.14; 1.1, 1.2 respectively) [51,52] (Supplementary material online,
Fig. S3e). However neither study had included a COPD comorbidity se-
verity or change measure.
3.1.9. RD comorbidity severity in HF and mortality; meta-analysis
Seven primary studies reported the adjusted association betweenHF
and renal dysfunction and all-cause mortality, with an individual study
median follow-up ranging from 20 to 38 months. Out of 69,520 HF pa-
tients, 28,596 (41%) had ‘any’ renal dysfunction (range 36 to 70%).
Over follow-up, 51% of HF patients with renal dysfunction died com-
pared to 42% of those without renal dysfunction, with a combined ad-
justed mortality risk of HR 1.52 (1.34, 1.71) (Fig. 4).Fig. 4. Association between HF and renal dysfunction comorbidity and all-cause mortality. Ren
gender (G), ethnicity (E), social (S), risk factors (R), comorbidities (C), aetiology (At), heart faiGalbraith plot identiﬁed two studies as being heterogeneous (Sup-
plementary material online, Fig. S1c). Following removal of a study
with a higher proportion ofmales (76%) and a lowermean ejection frac-
tion (32%) [18] and another with an older population (mean age,
76 years) and a lower proportion ofmales (43%) [53], heterogeneity be-
came non-signiﬁcant (I2 = 0%, p= 0.825). The pooled effect estimate
increased (HR 1.62; 1.59, 1.66) and there was no signiﬁcant evidence
of publication bias (Egger test p= 0.56) (Fig. S2c).
Five RD severity stratiﬁed studies reported adjusted associations be-
tween HF and all-cause mortality. Out of 64,257 HF patients, 24,349
(38%) had moderate RD and 3784 (6%) had severe RD. Over follow-up,
63% ofHFpatientswith severe and 48%withmoderate RDdied compared
to 42% of patients without RD. Random effects meta-analysis (including
an additional study from a prior review) [28] was performed, stratiﬁed
by severity group (Fig. 5)which showed the following adjusted estimates
of association with all-cause mortality: mild renal dysfunction (HR 1.01;
0.84, 1.22), moderate renal dysfunction (1.21; 1.18, 1.24), and severe
RD (2.01; 1.60, 2.52). This represents an estimated 80% increase in mor-
tality risk between moderate and severe RD. The association between
the severity subgroups and the study effect estimates was signiﬁcant
(p b 0.001). Using meta-regression, when the upper eGFR limit for each
study deﬁned severity category (x-axis) was plotted against their associ-
ated hazard ratio (y-axis), there was a ‘dose response’ association be-
tween HF, reducing eGFR and increasing mortality (Fig. 6).
3.1.10. RD comorbidity severity change in HF and mortality; meta-analysis
Five HF studies investigated worsening renal function (WRF) from
hospital admission baseline to discharge or study deﬁned endpoint.
Random effects meta-analysis (including two further studies from theal dysfunction comorbidity deﬁned by eGFR b60 mL/min/m2. Adjusted variables: age (A),
lure severity (Sv), drugs (D), laboratory (L), physical (P), ejection fraction (Ef).
Fig. 5.Association betweenHF and renal dysfunction comorbidity and all-causemortality stratiﬁed by severity. Adjusted variables: age (A), gender (G), ethnicity (E), social (S), risk factors
(R), comorbidities (C), aetiology (At), heart failure severity (Sv), drugs (D), laboratory (L), physical (P), ejection fraction (Ef) *from prior systematic review [28]. **Test of association be-
tween the severity subgroups and the study effect estimates was performed using random effects meta-regression with Monte Carlo permutations to calculate the p value.
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niﬁcant HR for mortality which increased from 1.53 (1.09, 2.14) in the
moderate change group to 2.29 (1.63, 3.21) in the severe change
group (Fig. 7). The association between the severity change subgroup
and the study effect estimates was non-signiﬁcant (p = 0.20) but
both change groups were independently and signiﬁcantly associated
with mortality (p b 0.05). One study showed that the monthly percent-
age reduction in eGFR of ≥1%was associated with an adjustedmortality
risk of HR3.6 (2.2, 5.7) [54] and a linear relationshipwas found between
increasing eGFR and all-cause mortality risk in four other studies
[55–57].3.1.11. RD comorbidity in HF and mortality; general prognostic factor and
model studies
The association between HF and RDwith all-cause mortality, showed
estimates ranging fromHR 1.35 to 2.27 in the 11 ‘general’ prognostic fac-
tor studies andHR1.37 to 5.22 in the 4 prognosticmodel studies (Supple-
mentary material online, Fig. S3f–g). Younger age (b85 years) was
associated with increased mortality risk from RD in HF [45]. RD was in-
cluded in 4 ‘general’ prognostic factor studies and one model study by a
severity indicator and in one ‘general’ factor study by severity change
(pre-hospital WRF) [58].Fig. 6. All-cause mortality risk by upper eGFR severity category limit in HF. All-cause mo3.1.12. RD comorbidity severity in HF and hospital admissions
Two studies focused on the association between RD severity and
the risk of all-cause hospital admissions. In one study, an eGFR of
N53mL/min compared to b35mL/minwas associatedwith a signiﬁcant
reduction in hospital admissions (HR 0.77; 0.56, 1.06) [24]. In another
study follow-up, 66% of patients without RD experienced a hospital ad-
mission compared to 68% of those with moderate RD (HR 1.16; 1.06,
1.27) and 73% of those with severe RD (HR 1.77; 1.16, 2.69) [18,56].
Only two studies focused onWRF and hospital admissions with signiﬁ-
cant association in one [59] (HR1.57; 1.2, 2.2) and non-signiﬁcant in an-
other [60].
There was one ‘general’ prognostic factor study and one prognostic
model study that had identiﬁed RD status as a signiﬁcant factor for hos-
pital admission (adjusted HR 1.32; 1.1, 1.5 and OR 1.09; 1.0, 1.1 respec-
tively) [52,61]. Both studies had not assessed RD severity or change.
3.1.13. HF and other non-CVD comorbid diseases
A single study focused on the association between rheumatoid ar-
thritis and all-causemortality inHF showing an independent and signif-
icant effect (HR 1.89; 1.3, 2.8). Eleven HF ‘general’ prognostic factor and
model studies investigatedmortality for comorbid arthritis (n= 2), de-
mentia (n=5), cancer (n=10), other lung disease (n=2) or liver dis-
ease (n = 3) (the range of estimates is reported in Supplementaryrtality risk plotted against upper eGFR severity category limit (study deﬁned) in HF.
Fig. 7.Association betweenHF and renal dysfunction comorbidity and all-causemortality stratiﬁedby severity change. Adjusted variables: age (A), gender (G), ethnicity (E), social (S), risk
factors (R), comorbidities (C), aetiology (At), heart failure severity (Sv), drugs (D), laboratory (L), physical (P), ejection fraction (Ef) *from previous systematic review [29]. **Test of as-
sociation between the severity subgroups and the study effect estimates was performed using random effects meta-regression with Monte Carlo permutations to calculate the p value.
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mission HFmodel study included other diseases such as dementia, can-
cer and liver disease [49,52,62–63]. All additional diseases had been
included by status and not a severity or change indicator.4. Discussion
This systematic review reports the current prognostic evidence in
non-selected HF populations on the impact of non-CVD comorbidity
and severity on mortality and hospital admission outcomes. There
were 68 primary HF studies covering nine non-CVD comorbid condi-
tions. Around half the studies identiﬁed had a chronic disease as the pri-
mary comorbidity focus and the other half were a mix of ‘general’
prognostic factor and model studies. Most studies (93%) focused on
mortality and only 16% included hospital admissions outcomes. Meta-
analysis was only possible for the mortality outcome as there were
few primary comorbidity studies for hospital admissions. Furthermore,
no prognosis studies on HF comorbidity and quality of life outcome
were identiﬁed using the study inclusion criteria despite the fact that
HF is associated with poor quality of life [64,65] that worsens as the dis-
ease progresses [66].
Most of the current evidence is on prevalent comorbidity in HF,
which were RD, DM or COPD and ﬁve other conditions which included;
arthritis, dementia, cancer, other lung disease or liver disease. In the
non-selected HF population, non-cardiovascular comorbidity was asso-
ciated with increasing likelihood of hospital admissions and higher
mortality, but the prognostic risk estimates did not differ by the type
of disease or the chosen outcomes. In terms of the increasing comorbid-
ity severity and change in HF, there was scarce evidence even in the
commonly prevalent conditions of DM and COPD, with exception of
RD where worsening renal failure has been investigated. Whilst much
of this evidence is highlighting the importance of non-cardiovascular
comorbidity status in HF, there is still a lack of evidence on how the full-
er range of comorbidity severity and changemight be incorporated into
HF prognosis. Prognostic models thus far, have incorporated non-
cardiovascular comorbidity status as a prognostic indicator for mortali-
ty and some for hospital admissions, but the clear evidence gap is
around severity and change for each comorbid condition, as well as
what happens to the model when patients suffer from multiple non-
cardiovascular conditions at the same time.Whilst comorbiditymay have been considered as a confounding fac-
tor in quality of life studies or in individual studies for selected HF
groups [65,67], there has been no systematic approach to investigating
comorbidity, severity and change in quality of life studies. The implica-
tions and importance of these evidence gaps are that the full spectrum
of HF patients and populations who experience the broadest range of
non-cardiovascular comorbidity, do not have the full range of prognos-
tic evidence that applies to the life course of outcomes from diagnosis,
change in quality of life, end-stage disease, hospital admissions and ﬁ-
nally death.
This review showed that for the examples of DM, COPD and RD
there were strong and independent associations with mortality (es-
timated 34 to 52% higher risk) and hospital admissions (estimated
28 to 77% higher risk) in non-selected HF. The magnitude of associa-
tion between different chronic disease comorbidities and mortality
or admissions in HF was not signiﬁcantly different and these ﬁndings
are important for three main reasons. First, it is well recognised that
the latency period between chronic disease comorbidity exposure
and outcome is likely to be long. In HF, comorbidity exposure often
occurs many years prior to the onset of the index HF disease or sub-
sequent to its onset, which leads to later small to moderate exposure
effects that can be difﬁcult to detect. Second, comorbidity status is
not static and will change over the life course progression of the
HF, yet cumulative effects from disease onset to outcomes maybe
similar across diseases [68]. Third, HF is a disease that predominately
occurs in older people, which means that incorporation of comorbid-
ity in prognosis requires the cumulative assessment of ageing and HF
and comorbidity severity and its change over time. The long latency
period between comorbidity exposure and outcome and the dynam-
ic status of comorbidity exposure leads to the hypothesis that prog-
nosis approaches that capture a change in exposure status may
yield better prognostic estimation.
In terms of this systematic review, the focus was on non-selected HF
populations. There have been other reviews [69–71] which havemostly
included comorbidities investigated in selected populations. Examples
include trial studies such as SOLVD [72], BEST [73], DIG [74] and other
observational studies [75–80]. Whilst these reviews summarize the im-
portance of comorbidity in speciﬁc heart failure groups we wanted to
synthesise the evidence on comorbidity in the broadest population of
heart failure, where the evidence is more limited, but where the range
of comorbidity is experienced.
105C.A. Rushton et al. / International Journal of Cardiology 196 (2015) 98–1065. Strengths and limitations
This systematic review is a comprehensive investigation of co-
morbidity in non-selected HF which has identiﬁed prognostic
follow-up studies that focused on comorbidity as a primary prognos-
tic factor or included comorbidity in a ‘general’ prognostic factor or
model study. The review methods used validated strategies and
were peer reviewed, articles were multi-sourced and there was a
structured approach to data extraction and synthesis in line with
current guidelines on prognostic studies [20,21]. The inclusion of
studies was based on standard deﬁnitions for the HF population,
non-cardiovascular chronic diseases and the outcomes of quality of
life, hospital admissions and mortality, but eligible studies may
have been excluded particularly of non-English publications. We
performed detailed data extraction and quality appraisal of each
study to allow for appropriate quantitative synthesis.
The review focuswas on aHFdeﬁnition that did not select groups by a
HFmechanism, ejection fraction or aetiology, as the primary interest was
to report the current evidence on the inﬂuence of non-cardiovascular co-
morbidity on outcomes in the broadest HF population. In terms of includ-
ing eligible HF studies, most studies had used a clinical diagnosis, some
hadused administration codes but studies based on self-report or diuretic
prescription had been excluded. Diagnostic criteria used to deﬁneHFmay
vary, which may inﬂuence prognosis estimates, but our approach pro-
vides a reasonable perspective on HF and common comorbidity. The co-
morbidity deﬁnition was also based either on clinical criteria in primary
studies or combination of large administrative databases or patient self-
report. Again this approach to deﬁnitions could potentially inﬂuence
estimates but the synthesis of large samples is likely to provide the best
estimation of HF prognosis.
Themeta-analysis only included studies where the comorbidity was
the primary focus of the investigation, but the quantitative synthesis of
observational studies is subject to heterogeneity across studies. Whilst
clear inclusion criterion helped to minimise selection issues, Galbraith
plots [34] and sensitivity analysis were used to explore the inﬂuence
of heterogeneity on the estimates of association between the non-
cardiovascular comorbidity and HF outcomes. The risk of study bias
was assessed using funnel plots and Egger tests [35] and only studies
with moderate or low risk of bias were included in the analysis. We
also ensured that for the ‘general’ prognostic factor and model studies,
where the under-reporting of comorbidity exposures may introduce
bias,meta-analysis was not performed. The ability to accurately account
for confounding is limited in meta-analysis of observational studies
without access to individual patient data. However the consistency of
the magnitude of estimates across the different studies identiﬁed sug-
gests that the combined estimate takes account of a range of important
confounders, but cannot exclude residual confounding.6. Conclusions
Comorbidity prognosis studies for non-selected HF populations have
to date focused on hospital settings and the outcome of mortality, show-
ing that the impact of comorbidities onHFmortality is similar across nine
different non-cardiovascular diseases.Much of the evidence is centred on
RD, and lesser evidence on DM and COPD, despite the fact that there is a
range of common non-cardiovascular conditions that may occur in the
older person across the spectrumof HF in the general population. Comor-
bidity severity change is beginning to be identiﬁed as an important indi-
cator of mortality and hospital admissions in non-selected HF, but few
prognostic models for HF have taken account of individual comorbidity
severity or consider change in inﬂuencing prognostic outcomes and the
clearest gap is when there are multiple non-cardiovascular conditions
in the same HF patient. Further investigation of the interplay between
HF and comorbid severity is required and for the range of life course out-
comes from diagnosis to death.Conﬂicts of interest
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